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Characterization of a recently 
detected halogenated aminorex 
derivative: para-fluoro-4-
methylaminorex (4′F-4-MAR)
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Despite the fact that 33% of the new psychoactive substances seized in 2015 were synthetic cathinones, 
the number of these derivatives has been decreasing in the last years, probably as a consequence of 
the unfavourable effects reported by users. Thus, the list of possible cathinone analogues is expected 
to get shorter, and it is likely that the same moiety changes applied for the preparation of synthetic 
cathinones will be applied in the near future to other stimulants in the search for favourable alternatives 
to controlled substances. This is evidenced by the increase in newly reported substances belonging 
to stimulant classes other than cathinones. One of the possible candidates for a new backbone from 
which to base new stimulants is aminorex, which is classified as a Schedule I substance by the Drug 
Enforcement Administration. Three derivatives have been reported until now: 4-methylaminorex or 
4-MAR (also categorized as a Schedule I substance), para-methyl-4-methylaminorex (4,4′-DMAR) and 
3′,4′-methylenedioxy-4-methylaminorex (MDMAR). Recently, the new halogenated 4-MAR derivative, 
para-fluoro-4-methylaminorex, characterised in this work (and abbreviated as pF-4-methylaminorex 
or 4′F-4-MAR) was detected by the Slovenian police. In the present work, 4′F-4-MAR has been 
characterized by high resolution mass spectrometry and nuclear magnetic resonance in a sample 
obtained from an anonymous consumer. This research shows that the same modifications applied 
for the preparation of synthetic cathinones are being used to prepare new stimulants based on the 
aminorex backbone.
The use of synthetic stimulants has increased in Europe in the last years, based on the seizures reported by the 
European Monitoring Centre for Drug and Drug Addiction (EMCDDA) in its 2017 Report1. According to this 
report, 33% of the substances seized in 2015 were synthetic cathinones, and 6% phenethylamines1. Synthetic 
cathinones are, nowadays, the second largest group of new psychoactive substances (NPS) monitored by the 
EMCDDA, and the most frequently seized NPS in 20151. In the last years, the characterization of novel synthetic 
cathinones has been an on-going topic for forensic laboratories, showing that modifications of the cathinone moi-
eties are the most frequent option for the production of novel stimulants2–9. Nonetheless, the number of new syn-
thetic cathinones reported every year is decreasing1, and the effects profile of the newest cathinone derivatives as 
reported by users have been unfavourable (especially when compared to older cathinone analogues)10. While the 
cathinone backbone appears to be capable of tolerating highly bulky as well as polar substitutions and additions 
while retaining psychoactivity, it seems that the list of possible analogues is getting shorter. Based on this trend, it 
is expected that in the next years, these modifications will be keep being applied to other stimulant classes in the 
search for favourable (to users) alternatives to controlled substances. This is evidenced by the increase in newly 
reported substances belonging to stimulant classes like the phenethylamines and piperazines1.
Over the past few years, the cathinone family has been the most common starting point for the produc-
tion of analogs that belong in the stimulants class11. Several other substance families have been used, in much 
lesser instances, as a backbone to produce analogs, such as amphetamine (2-FA, 3-FA, 4-FA)12, phenmetrazine 
(3-FPM)13, methylphenidate14, etc. There are not many cases analogs of aminorex15, so it remains a possible choice 
for producers of NPS to explore. Aminorex (Fig. 1) was patented by McNeil Laboratories in 1964 (US Patent 
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3,161,650) as a new central nervous system stimulant16. Aminorex was used in different countries as an appetite 
suppressor17, but was rapidly withdrawn due to the pulmonary hypertension it produced, which was linked with 
several deaths18,19. In the United States, aminorex is classified as a Schedule I substance by the Drug Enforcement 
Administration (DEA)20. The most well-known aminorex derivative is 4-methylaminorex or 4-MAR (Fig. 1), also 
patented by McNeil Laboratories in 196621. Several years ago, it was discovered that 4-MAR produces stimulant 
effects similar to those of cocaine22–24, as well as several neurochemical effects complications derived from its 
use25, leading to a fatality related to this compound26. For this reason, 4-MAR is also categorized as a Schedule I 
substance in the U.S.20.
In 2014, para-methyl-4-methylaminorex (4,4′-DMAR) (Fig. 1), a novel 4-MAR derivative, was reported and 
characterized15,27. Together with Europol, EMCDDA published an early warning notification in 2014, notifying 
of the involvement of 4,4′-DMAR in several deaths in Europe, 8 of them in Hungary (June 2013) and 18 in the 
United Kingdom (between June and December 2013)28. Additionally, EMCDDA-Europol published a joint report 
providing all the information available for 4,4′-DMAR29. One year later, the European Union decided to apply 
control measures to this aminorex derivative30. Nevertheless, in 2014 another 4-MAR derivative was reported 
and characterized, the 3′,4′-methylenedioxy-4-methylaminorex or MDMAR (Fig. 1)31. At the time of writing this 
paper, no additional information has been found for this compound.
The development of aminorex derivatives by modification of the aromatic ring has probably been carried 
out based on the “successful” synthesis of novel synthetic cathinones that use the same methodology. Two of the 
reported derivatives presented a para-methyl (4,4′-DMAR) and a 3,4-dioxane (MDMAR) moieties. These substi-
tutions can be easily found in well-known synthetic cathinones: using the structure of methcathinone32, mephe-
drone (4-methyl-methcathinone or 4-MMC)33 was synthetized by adding a para-methyl moiety, and methylone 
(3,4-methylenedioxy-N-methylcathinone or bk-MDMA)34 by adding a 3,4-dioxane moiety (Fig. 2). Moreover, 
4-FMC (4-fluoromethcathinone or flephedrone)35 and the recently reported 4-CMC (4-chloromethcathinone or 
clephedrone)36, were also synthetized based on different aromatic substitutions of methcathinone (Fig. 2). In this 
case, halogen atoms were used as para-substituents of the aromatic ring, producing novel active stimulants. In the 
light of this information, it would not be surprising that, in the next years, para-methoxy or para-chloro 4-MAR 
derivatives will appear in the streets.
Recently, a new halogenated 4-MAR derivative was detected by the Slovenian Police37, and reported in lit-
erature38. In the present study, para-fluoro-4-methylaminorex was fully characterized in a sample obtained 
from an anonymous Polish consumer. The compound was named as 4′F-4-MAR (or pF-4-methylaminorex), 
Figure 1. Structure of aminorex and its reported derivatives, including the new derivative reported in this work.
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following a similar nomenclature to that used for other aminorex derivatives. Its characterization was performed 
by ultra-high performance liquid chromatography-high resolution mass spectrometry (UHPLC-HRMS) and 
two-dimension nuclear magnetic resonance (NMR) experiments. Analyses with gas chromatography coupled 
to mass spectrometry with electron ionization (GC-MS), Fourier-transformed infrared spectroscopy (FTIR), 
as well as 1H and 13C NMR experiments were also performed in order to provide as much information as possi-
ble. Additionally, this research illustrates how the same moiety changes applied for the preparation of synthetic 
cathinones are being used to prepare new stimulants based on the 4-MAR structure. All analytical information 
provided in this work will be useful for the identification of 4′F-4-MAR or for future 4-MAR derivatives in foren-
sic laboratories.
Results
Identifying the 4′F-4-MAR. When the compound was injected into the UHPLC-HRMS, a single chroma-
tographic peak at 2.63 min was observed in the total ion chromatogram. Figure 3 shows the low energy and high 
energy spectra obtained by HRMS for this chromatographic peak. The low energy spectrum corresponding to 
this peak showed an ion at m/z 195.0933, which would correspond to the protonated molecule of the compound 
([M + H]+) (Fig. 3A). The elemental composition for [M + H]+ was determined to be C10H12FN2O+ (−0.1 mDa) 
based on the accurate-mass observed. According to the aminorex elemental composition (C9H10N2O)31, this 
putative derivative should contain an extra methyl group and a fluorine atom on the aminorex structure. The 
high energy spectrum of the chromatographic peak showed six important fragment ions (Fig. 3B). Fragment 1 
(C9H11FN+, −0.2 mDa) corresponds to a CHNO loss. This specific loss has been reported in literature for two 
aminorex derivatives, the para-methyl-4-methylaminorex (4,4′-DMAR) and the 3′,4′-methylenedioxy-4-meth-
ylaminorex (MDMAR)15,31. The loss of CHNO from [M + H]+ produces the formation of an N-epoxide structure 
on the molecule, in the same way than 4,4′-DMAR and MDMAR15,31. Fragment 3 (C9H8F+, −0.1 mDa) would 
derive from Fragment 1 after an ammonia molecule loss, according to its elemental composition. Fragment 5 
(C9H7+, −0.1 mDa) produced after a HF molecule loss from Fragment 3, did not provide any information about 
the position of the fluorine atom or of the methyl group. Nevertheless, Fragment 6 (C7H6F+, 0.0 mDa) would 
correspond to a fluorotropylium ion. This fragment ion is in concordance with the tropylium ion observed for the 
4,4′-DMAR15. Fragment 6 would indicate that the fluorine atom could be on the aromatic ring. Nevertheless, the 
accurate-mass fragmentation observed was not enough for confirming the identity of the compound.
In order to find the location of the methyl group and establish the position of the fluorine atom in the aromatic 
ring, two two-dimension NMR experiments (COSY and HSQC) were performed. Figure 4 shows the COSY 
spectrum (A) and the HSQC spectrum (B) of the putative aminorex derivative. The doublet at δ = 1.32 ppm, 
which integration was 3 in the COSY spectrum (Fig. 4A, and thus in a 1H spectrum) indicated the presence of a 
methyl group in the structure, as supposed based on the elemental composition (C10H11FN2O) determined by 
HRMS. The HSQC spectrum established that the carbon atom of this methyl was at δ = 21.50 ppm in the 13C 
spectrum (Fig. 4B), as expected for this moiety. According to the couplings observed in the COSY, this methyl 
group is near to a tertiary carbon (multiplet at δ = 3.90 ppm in 1H spectrum -Fig. 4A- which integrates for 1, 
and δ = 68.31 ppm in 13C -Fig. 4B-). Moreover, this tertiary atom is coupled to another tertiary atom (doublet at 
Figure 2. Structure of methcathinone and its reported derivatives.
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δ = 4.90 ppm in 1H spectrum -Fig. 4A- which integrates for 1, and δ = 88.28 ppm in 13C -Fig. 4B-), which mul-
tiplicity indicates that it has only one hydrogen to be coupled (the first tertiary carbon mentioned). The high δ 
observed for this second tertiary atom indicates that it should be near to electronegative moieties such as oxygen 
atoms, nitrogen atoms or aromatic rings. These observations established the methyl group to be on the position 4 
of the 4,5-dihydrooxazol ring, similarly to 4-MAR22, 4,4′-DMAR15,31, and MDMAR15,31. Moreover, this position 
was in concordance with the CHNO loss observed in HRMS (Fragment 1 in Fig. 3), which can only occur if the 
methyl group is in this position. Once the position of the methyl group was established, the position of the fluo-
rine atom on the aromatic ring was determined. The aromatic signals observed in the COSY spectrum (signals 
at δ = 7.07 and 7.31 in the 1H spectrum) presented the typical pattern of a para-substituted aromatic ring. Based 
on this fact and considering the fluorotropylium ion observed in HRMS (Fragment 6 in Fig. 3), the fluorine atom 
should be in position 4 of the aromatic ring. With this information, the novel aminorex derivative should be the 
para-fluoro-4-methylaminorex, which could be known as 4′F-4-MAR based on the nomenclature used for the 
other aminorex derivatives reported previously.
Once the structure of this compound was established, all the NMR signals observed in the COSY and HSQC 
(and thus the 1H and 13C signals) were successfully assigned to the proposed structure. Figure 4A,B show the 
signal assignation based on the structure of 4′F-4-MAR. The fragmentation pathway of 4′F-4-MAR was also 
proposed based on the accurate-mass fragmentation (Fig. 3C).
In order to provide a complete characterization of the compound and facilitate the identification of 4′F-4-MAR 
by forensic laboratories, GC-EI-MS and FTIR analyses were also carried out. The EI spectrum and FTIR spec-
trum can be found in Supplementary Information (Figs S1 and S2, respectively). The 1H and 13C NMR spectra 
are also provided (Figs S3 and S4, respectively). Additional information about sample treatment and instrument 
conditions for GC-MS and FTIR can be found in Supplementary Information.
Discussion
A decrease in the number of new cathinones detected every year has been observed in the last few years, together 
with an increase in other groups of stimulants such as phenethylamines1. It appears that the list of possible cathi-
none analogues that have not been synthesized is dwindling, and producers of NPS are struggling to find substi-
tutions that will yield an active compound39. Although theoretically the possibilities are nearly endless, there is a 
limit to the substitutions that the cathinone backbone can tolerate and still yield an active compound. It appears 
that the limit has nearly been reached, and producers appear to be exploring other backbones from which to 
create new psychoactive substances.
One example is amphetamine. In the past year, we have seen the first detection of 2-FEA, 3-FEA, and 4-FEA, 
three new compounds based on the amphetamine backbone40. These compounds follow the same modification 
pattern of the aromatic ring to create a new analog41. Nevertheless, they have reached limited popularity due to 
their lower effects and large required doses respect to amphetamine, as each carbon added to the amine chain of 
amphetamine appears to make the compound less potent42.
The aminoindane family has also been explored with the same pattern of limited success, with compounds 
such as MDAI, 5-IAI, or 2-AI being reported43. The same can be observed with the phenmetrazine (e.g. 3-FPM)13.
Figure 3. UHPLC-HRMS information of the putative aminorex derivative. (A) Low energy spectrum. (B) High 
energy spectrum. (C) Proposed fragmentation pathway once identified the new aminorex derivative.
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These seem to yield compounds that are either not potent or popular enough to make their production profita-
ble. The logical next step by producers is to continue exploring possible new families from which to create new 
analogues.
There are three distinct advantages that likely motivated the decision of synthesizing another aminorex analog, 
specifically 4′F-4-MAR: ease of synthesis, available data on effects, and users appeal.
There are discussions on synthesis forums, dating to around 2003, where a functioning synthesis is discussed 
and perfected44. For that synthesis, the described precursor is the same one used in 4-FA synthesis45, which means 
that the precursor for an NPS that is banned in several countries can be repurposed to produce a new substance 
not currently under strict restrictions.
Additionally, as can be seen in the archived hive thread referenced above about the synthesis of 4′F-4-MAR, 
bioassays by the forum users are positive, describing pleasant effects at fairly low doses and no immediate negative 
side effects38. This is very useful for producers because it removes some of the uncertainty regarding the recre-
ational potential of this substance. Often there is no available data about effects of a new NPS on humans, and 
favourable in vitro and/or animal studies do not translate well to human effects.
The Aminorex family appears to be well-liked by forum users, as it is not explicitly mentioned in existing 
analog laws like the German NpSG46 and because of an expectation of recreational potential stemming from the 
effects and popularity of 4-Methylaminorex before it was banned47. Consequently, users will likely be willing to 
sample 4′F-4-MAR, and not much marketing will surely be needed by producers or vendors.
As final note, an unknown sample suspected to contain anaminorex derivative has been analysed by HRMS, 
allowing the tentative identification of the recently reported para-fluoro-4-methylaminorex or 4′F-4-MAR. The 
unequivocal identification and structure confirmation was performed by two-dimension NMR experiments 
Figure 4. Two-dimension NMR experiments, with signal assignation, performed for the identification of the 
novel aminorex derivative. (A) COSY spectrum. (B) HSCQ spectrum.
6Scientific RepoRts |          (2019) 9:8314  | https://doi.org/10.1038/s41598-019-44830-y
www.nature.com/scientificreportswww.nature.com/scientificreports/
(COSY and HSQC). The compound was also analysed by GC-EI-MS, FTIR, 1H and 13C NMR in order to provide 
additional information to forensic laboratories.
Based in the glorification of the effects of 4,4′-DMAR and 4-MAR by users on online forums after they were 
banned, it is reasonable to think that the aminorex family is an attractive candidate for the new stimulant back-
bone that producers are looking for47–50. 4′F-4-MAR appears to be the next analog that has been released. If the 
users evaluate this compound positively in forum discussions and demand is high, it is likely that producers will 
manufacture further analogues. As such, it is possible that the number of stimulants based on the cathinone 
backbone reported every year will keep decreasing while the number of stimulants based on aminorex backbone 
will continue to rise.
Data available on aminorex analogues from forums, where advanced pharmacology and synthesis are dis-
cussed, allows for a rare glimpse of the possible factors that influence the process of NPS production and distribu-
tion. Our findings support the theory that this process is relatively complex and involves a more-than-rudimentary 
grasp on chemistry, pharmacology, and business concepts by producers of these novel psychoactive substances.
The information provided in this paper will be of help to analytical/forensic laboratories for the identification 
of 4′F-4-MAR or for potential 4-MAR derivatives that may appear in the near future.
Methods
Research chemical sample. The research chemical sample was deferred by an anonymous user to Energy 
Control’s51 for its analysis. This sample was suspected to be a novel aminorex derivative based on the information 
provided by the anonymous user, so this was the premise in order to identify it.
Reagents and chemicals. HPLC-grade water was obtained from a Milli-Q system (Millipore, Bedford, 
MA, USA). HPLC-grade methanol (MeOH) and acetonitrile (ACN), acetone, formic acid (HCOOH) and sodium 
hydroxide (NaOH) were acquired from Scharlau (Scharlab, Barcelona, Spain). Leucine enkephalin was bought 
from Sigma-Aldrich (St. Louis, MO, USA). Deuterated chloroform (CDCl3) was purchased from Sigma-Aldrich.
sample treatment. 10 mg of sample were extracted with 1 mL of acetone in an ultrasonic bath for 15 min. 
After centrifugation, the supernatant was ten thousand-fold diluted with HPLC-grade water, and 20 µL of the 
extract were injected in the UHPLC-HRMS system.
For NMR analysis, approximately 15 mg of sample were dissolved in 0.6 mL of CDCl3.
Instrumentation. Analysis was performed using an ACQUITY UPLC system (Waters, Mildford, MA, 
USA) coupled to a XEVO G2 QTOF mass spectrometer (Waters Micromass, Manchester, UK).A CORTECS C18 
(Waters) analytical column (100 × 2.1 mm,2.7 µm particle size) at a flow rate of 0.3 mL/min was used. The column 
temperature was set to 40 °C. The mobile phases used were H2O and MeOH, both with 0.01% HCOOH. The ini-
tial percentage of organic mobile phase was changed as follows: 10% at 0 min, 90% at 14 min linearly increased, 
90% at 16 min, and return to initial conditions at 18 min. The injection volume was 20 µL. Nitrogen (Praxair) was 
used as desolvation (1000 L/h) and nebulizing gas. TOF resolution was ~20000 at FWHM (at m/z 556). A mass 
range from m/z 50 to 1000 was acquired. The capillary and cone voltage were set to 0.7 kV and 20 V, respectively. 
Argon 99.995% (Praxair) was used as a collision gas. The interface temperature was set to 650 °C and the source 
temperature to 120 °C.
In MSE experiments, the low energy function (LE) used a collision energy of 4 eV while the high energy 
function (HE) applied a collision energy ramp from 15 to 40 eV. In this way, information about the protonated 
molecule and adducts (if present) and fragment ions48 were obtained in a single analysis.
Calibration of the mass-axis was daily performed using a mixture of 0.05 M NaOH:5% HCOOH (50:50), 
25-fold diluted with ACN:H2O (80:20). A 2 µg/mL leucine enkephalin solution in ACN:H2O (50:50) with 0.1% 
HCOOH was used as lock-mass UHPLC-HRMS data were acquired in continuum mode (MassLynx, version 4.1, 
Waters) and processed with UNIFI (version 1.8, Waters).
A Bruker Ascend 400 MHz spectrometer equipped with a SampleCase autosampler (Bruker, Etlingen, 
Germany) was used for NMR analysis. Data acquisition was performed at 303 K using CDCl3. The residual sol-
vents signals at δ = 7.24 ppm for 1H (CHCl3) and at δ = 77.23 ppm for 13C (CDCl3) were used as internal refer-
ences. Characterization of the compound was performed using 1H NMR, 13C NMR, correlated spectroscopy 
(COSY) and heteronuclear single quantum coherence (HSQC). NMR experiment data were collected using the 
Bruker Icon NMR 5.0.5 software (Bruker). MestreNova program was used for raw data processing (Mestrelab 
Research, Santiago de Compostela, Spain).
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